Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Wu, Jian Min ^a   Xu, Yan ^a   Skill, Nicholas J ^a   Sheng, Hongmiao ^a   Zhao, Zhenwen ^a   Yu, Menggang ^a   Saxena, Romil ^a   Maluccio, Mary A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOPHOSPHOLIPASE; LYSOPHOSPHOLIPASE D; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ENPP2 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; MULTIENZYME COMPLEX; PHOSPHODIESTERASE I; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL; LIVER CELL CARCINOMA; MALE; PROTEIN SECRETION; UPREGULATION; BIOSYNTHESIS; CELL STRAIN HEPG2; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; IMMUNOBLOTTING; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; NF-KAPPA B; PHOSPHODIESTERASE I; PYROPHOSPHATASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950445752     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-71     Document Type: Article

References (50)

1. Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009, 100:19-23. 10.1038/sj.bjc.6604784, 2634687, 19018262.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
3. Cooper AB, Wu JM, Lu D, Maluccio MA. Is Autotaxin (ENPP2) the Link between Hepatitis C and hepatocellular carcinoma?. J Gastrointest Surg 2007, 11:1628-1634. 10.1007/s11605-007-0322-9, 17902023.
4. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, Tejima K, Nishikawa T, Arai M, Yanase M, et al. Plasma ysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 2007, 81:1009-1015. 10.1016/j.lfs.2007.08.013, 17850827.
5. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992, 267:2524-2529.
6. Lee HY, Clair T, Mulvaney PT, Woodhouse EC, Aznavoorian S, Liotta LA, Stracke ML. Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem 1996, 271:24408-24412. 10.1074/jbc.271.40.24408, 8798697.
7. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000, 19:241-247. 10.1038/sj.onc.1203263, 10645002.
8. Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001, 61:6938-6944.
9. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006, 281:25822-25830. 10.1074/jbc.M605142200, 16829511.
10. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006, 26:5015-5022. 10.1128/MCB.02419-05, 1489177, 16782887.
11. Fox MA, Alexander JK, Afshari FS, Colello RJ, Fuss B. Phosphodiesterase-I alpha/autotaxin controls cytoskeletal organization and FAK phosphorylation during myelination. Mol Cell Neurosci 2004, 27:140-150. 10.1016/j.mcn.2004.06.002, 15485770.
12. Dennis J, Nogaroli L, Fuss B. Phosphodiesterase-Ialpha/autotaxin (PD-Ialpha/ATX): A multifunctional protein involved in central nervous system development and disease. J Neurosci Res 2005, 82:737-742. 10.1002/jnr.20686, 16267828.
13. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002, 158:227-233. 10.1083/jcb.200204026, 2173129, 12119361.
14. Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, Stracke ML. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 2003, 63:5446-5453.
15. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 2002, 1582:204-215.
16. van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007, 46:145-160. 10.1016/j.plipres.2007.02.001, 17459484.
17. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004, 279:17634-17639. 10.1074/jbc.M313927200, 14744855.
18. Kehlen A, Lauterbach R, Santos AN, Thiele K, Kabisch U, Weber E, Riemann D, Langner J. IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol 2001, 123:147-154. 10.1046/j.1365-2249.2001.01432.x, 1905967, 11168012.
19. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 2007, 28:365-386. 10.1210/er.2006-0031, 17431229.
20. Morris AJ, Smyth SS. Measurement of autotaxin/lysophospholipase D activity. Methods Enzymol 2007, 434:89-104. full_text, 17954243.
21. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog 2009,
22. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466. 10.1038/nature02924, 15329734.
23. Kawagoe H, Soma O, Goji J, Nishimura N, Narita M, Inazawa J, Nakamura H, Sano K. Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2). Genomics 1995, 30:380-384. 10.1006/geno.1995.0036, 8586446.
24. Hooghe B, Hulpiau P, van Roy F, De Bleser P. ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res 2008, 36:W128-132. 10.1093/nar/gkn195, 2447729, 18453628.
25. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The antiinflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001, 8:759-766. 10.1016/S1074-5521(01)00049-7, 11514225.
26. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA. NF-kB Inhibition in Human Hepatocellular Carcinoma and its Potential as Adjunct to Sorafenib Based Therapy. Cancer Letters 2009, 278:145-155. 10.1016/j.canlet.2008.12.031, 19303700.
27. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224. 10.1101/gad.1228704, 15371334.
28. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009, 15:539-550. 10.1016/j.ccr.2009.03.027, 19477432.
29. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995, 76:958-962.
30. Takahara N, Kashiwagi A, Maegawa H, Shigeta Y. Lysophosphati-dylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 1996, 45:559. 10.1016/S0026-0495(96)90024-4, 8622597.
31. Zhu Y, Lin JH, Liao HL, Verna L, Stemerman MB. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta 1997, 1345:93-98.
32. Kume N, Gimbrone MA. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994, 93:907-911. 10.1172/JCI117047, 293967, 7509351.
33. Chai YC, Howe PH, DiCorleto PE, Chisolm GM. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells: evidence for release of FGF-2. J Biol Chem 1996, 271:17791-17777. 10.1074/jbc.271.30.17791, 8663300.
34. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci 1998, 85:2805-2809.
35. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990, 344:160-162. 10.1038/344160a0, 2106627.
36. Murugesan G, Fox PL. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest 1996, 97:2736-2744. 10.1172/JCI118728, 507366, 8675684.
37. Coutant F, Perrin-Cocon L, Agaugué S, Delair T, André P, Lotteau V. Mature dendritic cell generation promoted by lysophosphatidylcholine. J Immunol 2002, 169:1688-1695.
38. Whalen MM, Doshi RN, Bader BW, Bankhurst AD. Lysophosphatidylcholine and arachidonic acid are required in the cytotoxic response of human natural killer cells to tumor target cells. Cell Physiol Biochem 1999, 9:297-309. 10.1159/000016324, 10749996.
39. Sautin YY, Jorgensen M, Petersen BE, Saulnier-Blache JS, Crawford JM, Svetlov SI. Hepatic oval (stem) cell expression of endothelial differentiation gene receptors for lysophosphatidic acid in mouse chronic liver injury. J Hematother Stem Cell Res 2002, 11:643-649. 10.1089/15258160260194785, 12201952.
40. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999, 154:537-541. 1849988, 10027411.
41. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T, et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007, 41:616-623. 10.1097/01.mcg.0000225642.90898.0e, 17577119.
42. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128. 10.1053/j.gastro.2006.01.006, 16618406.
43. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003, 3:573-588. 10.2174/1566524033479546, 14527088.
44. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979, 282:615-616. 10.1038/282615a0, 233137.
45. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002, 76:13001-13014. 10.1128/JVI.76.24.13001-13014.2002, 136668, 12438626.
46. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982, 42:3858-3863.
47. Everson GT, Polokoff MA. HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J Biol Chem 1986, 261:2197-2201.
48. Perilongo G, Shafford EA. Liver tumours. Eur J Cance 1999, 35:953-958.
49. Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 2000, 905:242-259.
50. Zhao Z, Xiao Y, Elson P, Tan H, Plummer SJ, Berk M, Aung PP, Lavery IC, Achkar JP, Li L, et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol 2007, 25:2696-2601. 10.1200/JCO.2006.08.5571, 17602074.